Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
InMed PharmaceuticalsINM | Open-market buy | 05/20–06/08 | 06/10 | 249,227 sh18 trades | $1.57avg. | $391,554.51 | No record | |
InMed PharmaceuticalsINM | Open-market buy | 05/20–06/08 | 06/10 | 249,227 sh18 trades | $1.57avg. | $391,554.51 | No record | |
InMed PharmaceuticalsINM | Open-market buy | 05/20–06/08 | 06/10 | 249,227 sh18 trades | $1.57avg. | $391,554.51 | No record | |
InMed PharmaceuticalsINM | Open-market buy | 05/20–06/08 | 06/10 | 249,227 sh18 trades | $1.57avg. | $391,554.51 | No record | |
InMed PharmaceuticalsINM | Open-market buy | 05/19 | 05/21 | 468,551 sh3 trades | $1.54avg. | $721,681.6 | +141.4% | |
InMed PharmaceuticalsINM | Open-market buy | 05/19 | 05/21 | 468,551 sh3 trades | $1.54avg. | $721,681.6 | +141.4% | |
InMed PharmaceuticalsINM | Open-market sale | 24/07/31 | 24/08/02 | 240 sh | $0.18 | $43.2 | −100.0% | |
Andrew HullDirector | InMed PharmaceuticalsINM | Open-market buy | 24/02/21 | 24/02/22 | 37,500 sh | $0.39 | $14,625 | +4947.2% |
Eric A. AdamsPresident & CEO | InMed PharmaceuticalsINM | Open-market buy | 24/02/20 | 24/02/21 | 41,600 sh | $0.36 | $14,976 | +1763.5% |